Ohcanbohtosat - Issa, Samar

Carbazole scaffolds in cancer therapy: a review from 2012 to 2018 Dahkki Issa, Samar, Prandina, Anthony, Bedel, Nicolas, Rongved, Pål, Yous, Saïd, Le Borgne, Marc, Bouaziz, Zouhair

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Regulation of microRNAs in Cancer Metastasis Dahkki Bouyssou, Juliette M.C., Manier, Salomon, Huynh, Daisy, Issa, Samar, Roccaro, Aldo M., Ghobrial, Irene M.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma Dahkki van der Meulen, Matthijs, Dirven, Linda, Bakunina, Katerina, van den Bent, Martin J., Issa, Samar, Doorduijn, Jeanette K., Bromberg, Jacoline E. C.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

NCOG-05. IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS Dahkki van der Meulen, Matthijs, Dirven, Linda, Habets, Esther, Bakunina, Katerina, Taphoorn, Martin, van den Bent, Martin, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Viečča ollesdeavstta Viečča ollesdeavstta

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation – an International Primary Central Nervous System Lymphoma Study Group project Dahkki Bromberg, Jacoline E., Doorduijn, Jeanette K., Illerhaus, Gerald, Jahnke, Kristoph, Korfel, Agniezka, Fischer, Lars, Fritsch, Kristina, Kuittinen, Outti, Issa, Samar, van Montfort, Cees, van den Bent, Martin J.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

CLRM-15 TRIAL IN PROGRESS: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT INHIBITOR OF BRUTON’S TYROSINE KINASE (BTKI) FOR RELAPSED/REFRACTORY P... Dahkki Soussain, Carole, Grommes, Christian, Issa, Samar, Ward, Renee, Peterson, Caryn, Cravets, Matt, Mathias, Anita, Sosa, Judith, Kirby, Brian, Ding, Zhaoqing, Yusuf, Isharat, Rose, Mark, Steinberg, Marcos, Tun, Han W

Viečča ollesdeavstta Viečča ollesdeavstta

Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI Dahkki Wieduwilt, Matthew J., Valles, Francisco, Issa, Samar, Behler, Caroline M., Hwang, James, McDermott, Michael, Treseler, Patrick, O’Brien, Joan, Shuman, Marc A., Cha, Soonmee, Damon, Lloyd E., Rubenstein, James L.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Fo... Dahkki Flinn, Ian W., van der Jagt, Richard, Kahl, Brad, Wood, Peter, Hawkins, Tim, MacDonald, David, Simpson, David, Kolibaba, Kathryn, Issa, Samar, Chang, Julie, Trotman, Judith, Hallman, Doreen, Chen, Ling, Burke, John M.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Dahkki Flinn, Ian W., van der Jagt, Richard, Kahl, Brad S., Wood, Peter, Hawkins, Tim E., MacDonald, David, Hertzberg, Mark, Kwan, Yiu-Lam, Simpson, David, Craig, Michael, Kolibaba, Kathryn, Issa, Samar, Clementi, Regina, Hallman, Doreen M., Munteanu, Mihaela, Chen, Ling, Burke, John M.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Extent of radiological response does not reflect survival in primary central nervous system lymphoma Dahkki van der Meulen, Matthijs, Postma, Alida A, Smits, Marion, Bakunina, Katerina, Minnema, Monique C, Seute, Tatjana, Cull, Gavin, Enting, Roelien H, van der Poel, Marjolein, Stevens, Wendy B C, Brandsma, Dieta, Beeker, Aart, Doorduijn, Jeanette K, Issa, Samar, van den Bent, Martin J, Bromberg, Jacoline E C

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial Dahkki van der Meulen, Matthijs, Dirven, Linda, Habets, Esther J J, Bakunina, Katerina, Smits, Marion, Achterberg, Hakim C, Seute, Tatjana, Cull, Gavin, Schouten, Harry, Zijlstra, Josée M, Brandsma, Dieta, Enting, Roelien H, Beijert, Max, Taphoorn, Martin J B, van den Bent, Martin J, Issa, Samar, Doorduijn, Jeanette K, Bromberg, Jacoline E C

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets Dahkki Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.

Viečča ollesdeavstta Viečča ollesdeavstta Viečča ollesdeavstta